@article{e77009463f9c481b8171c53a78377b34,
title = "Recommendations for the conduct of economic evaluations in osteoporosis: outcomes of an experts' consensus meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the US branch of the International Osteoporosis Foundation",
abstract = "Economic evaluations are increasingly used to assess the value of health interventions, but variable quality and heterogeneity limit the use of these evaluations by decision-makers. These recommendations provide guidance for the design, conduct, and reporting of economic evaluations in osteoporosis to improve their transparency, comparability, and methodologic standards.IntroductionThis paper aims to provide recommendations for the conduct of economic evaluations in osteoporosis in order to improve their transparency, comparability, and methodologic standards.MethodsA working group was convened by the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis to make recommendations for the design, conduct, and reporting of economic evaluations in osteoporosis, to define an osteoporosis-specific reference case to serve a minimum standard for all economic analyses in osteoporosis, to discuss methodologic challenges and initiate a call for research. A literature review, a face-to-face meeting in New York City (including 11 experts), and a review/approval by a larger group of experts worldwide (including 23 experts in total) were conducted.ResultsRecommendations on the type of economic evaluation, methods for economic evaluation, modeling aspects, base-case analysis and population, excess mortality, fracture costs and disutility, treatment characteristics, and model validation were provided. Recommendations for reporting economic evaluations in osteoporosis were also made and an osteoporosis-specific checklist was designed that includes items to report when performing an economic evaluation in osteoporosis. Further, 12 minimum criteria for economic evaluations in osteoporosis were identified and 12 methodologic challenges and need for further research were discussed.ConclusionWhile the working group acknowledges challenges and the need for further research, these recommendations are intended to supplement general and national guidelines for economic evaluations, improve transparency, quality, and comparability of economic evaluations in osteoporosis, and maintain methodologic standards to increase their use by decision-makers.",
keywords = "COST-EFFECTIVENESS ANALYSES, Cost-effectiveness, EXCESS MORTALITY, Economic evaluation, FRACTURE RISK REDUCTION, HEALTH, HIP FRACTURE, OLDER WOMEN, Osteoporosis, POSTMENOPAUSAL WOMEN, QUALITY-OF-LIFE, Recommendations, Reference case, TERIPARATIDE, VERTEBRAL FRACTURES, IMPACT",
author = "M. Hiligsmann and Reginster, {J. -Y.} and Tosteson, {A. N. A.} and Bukata, {S. V.} and Saag, {K. G.} and Gold, {D. T.} and P. Halbout and F. Jiwa and Lewiecki, {E. M.} and D. Pinto and Adachi, {J. D.} and N. Al-Daghri and O. Bruyere and M. Chandran and C. Cooper and Harvey, {N. C.} and Einhorn, {T. A.} and Kanis, {J. A.} and Kendler, {D. L.} and Messina, {O. D.} and R. Rizzoli and L. Si and S. Silverman",
note = "Funding Information: Conflict of interest MH has received research grant through institution from Amgen, Radius, and Teva, lecture fees from Radius, and paid advisory board from UCB. JYR has received research grant and/or consulting fees from Servier, Novartis, Negma, Lilly, Wyeth, Amgen, GlaxoSmithKline, Roche, Merckle, Nycomed-Takeda, NPS, IBSA Genevrier, Theramex, UCB, Asahi Kasei, Endocyte, Merck Sharp and Dohme, Rottapharm, Teijin, Teva, Analis, NovoNordisk, Ebewee Pharma, Zodiac, Danone, Will Pharma, Meda, Bristol Myers Squibb, Pfizer, Organon, Therabel, Boehringer, Chiltern, and Galapagos. KGS has received research funding from Amgen, Mereo, and Radius and has consulted for Amgen, Lilly, Radius, and Roche; he is on the National Osteoporosis Foundation Board of Trustees. DTG has received consulting fees from Amgen, Eli Lilly, and Radius. EML has received institutional grant/research support from Amgen, PFEnex, and Mereo; he has served on scientific advisory boards for Amgen, Radius, Shire, Alexion, Ultragenyx, and Sandoz; he serves on the speakers{\textquoteright} bureau for Shire, Alexion, and Radius; he is a board member of the National Osteoporosis Foundation, International Society for Clinical Densitometry, and Osteoporosis Foundation of New Mexico. JDA is an investigative site for clinical trials for Amgen, consultant and speaker for Amgen. OB received research grants from Biophytis, IBSA, Meda, Servier, and SMB and consulting fees from Biophytis, IBSA, MEDA, Servier, SMB, and TRB Chemedica. MC has received honoraria for speaking engagements with AMGEN and Eli Lilly and has served on the scientific advisory board of MSD. CC reports personal fees from Alliance for Better Bone Health, Amgen, Eli Lilly, GSK, Medtronic, Merck, Novartis, Pfizer, Roche, Servier, Takeda, and UCB. NCH has received consultancy, lecture fees, and honoraria from Alliance for Better Bone Health, Amgen, Merck Sharp & Dohme, Eli Lilly, Servier, Shire, UCB, Consilient Healthcare, and Internis Pharma. TAE has been scientific Advisory Board for AGnovos, consultant for Terumo, stock owner for PolyPid, and grant recipient from Orthofix. JAK reports grants from Amgen, grants from Lilly, grants from Radius Health, grants from UCB, other from Meda, outside the submitted work; and he is the principal architect of FRAX but derives no financial benefit. DLK has received research grants, advisory honoraria, and/or speaker honoraria from Amgen, Eli Lilly, Astrazenica, and Pfizer. ODM has been consultant for Amgen, Lilly, Pfizer, UCB, American Health Foundation (AHF), Gilead. RR has received consulting or lecture fees from Radius Health, CNIEL, Effryx, Theramex, Danone, and Nestl{\'e}. LS has received a National Health and Medical Research Council (NHMRC) grant (1127827) and a NHMRC Early Career Fellowship (1139826) for his research time. SS has received grant support from Amgen, Radius, and Lilly; he has received consulting fees from Amgen and Radius; he has served on scientific advisory boards for Lilly and Amgen; and he has served on speakers bureaus for Amgen, Lilly, and Radius. ANT, SVK, PH, FJ, DP, and NAD have no conflicts of interest to report. Funding Information: Acknowledgments This meeting was entirely funded by ESCEO which received an Unrestricted Educational Grant from IOF USA. IOF USA was partially funded through an Unrestricted Educational Grant from Radius Health. IOF USA and Radius Health were not involved in the selection of the participants, choice of the venue, and preparation of the program and were not consulted regarding the outcomes of the meeting, the content of the manuscript, or the selection of the Journal to which the manuscript was submitted. All these choices were made by the Scientific Advisory Board of ESCEO and by the authors of the manuscript without any external influence. The authors extend their appreciation to the Chair for Biomarkers of Chronic Diseases, King Saud University, Riyadh, Saudi Arabia, for its support. Funding Information: This meeting was entirely funded by ESCEO which received an Unrestricted Educational Grant from IOF USA. IOF USA was partially funded through an Unrestricted Educational Grant from Radius Health. IOF USA and Radius Health were not involved in the selection of the participants, choice of the venue, and preparation of the program and were not consulted regarding the outcomes of the meeting, the content of the manuscript, or the selection of the Journal to which the manuscript was submitted. All these choices were made by the Scientific Advisory Board of ESCEO and by the authors of the manuscript without any external influence. The authors extend their appreciation to the Chair for Biomarkers of Chronic Diseases, King Saud University, Riyadh, Saudi Arabia, for its support. Publisher Copyright: {\textcopyright} 2018, The Author(s).",
year = "2019",
month = jan,
doi = "10.1007/s00198-018-4744-x",
language = "English",
volume = "30",
pages = "45--57",
journal = "Osteoporosis International",
issn = "0937-941X",
publisher = "Springer",
number = "1",
}